Boehringer Ingelheim financials

Boehringer Ingelheim Revenue

Boehringer Ingelheim revenue was €20.62 b in FY, 2021

Embed Graph

Founding Date	1885

Embed Graph

Boehringer Ingelheim revenue breakdown by business segment: 20.8% from Animal Health, 74.2% from Human Pharmaceuticals and 5.0% from Other

Boehringer Ingelheim revenue breakdown by geographic segment: 44.4% from Americas, 23.8% from Asia/Australia/Africa and 31.8% from Europe

EUR	FY, 2019	FY, 2020	FY, 2021
Revenue	19.0b	19.6b	20.6b
Cost of goods sold	2.9b	2.6b	2.8b
Gross profit	16.1b	17.0b	17.8b
Gross profit Margin, %	85%	87%	86%
General and administrative expense	5.4b	5.6b	5.7b
Operating expense total	14.6b	16.1b	16.1b
Depreciation and amortization	1.2b	1.4b	1.1b
EBIT	3.8b	4.6b	4.7b
EBIT margin, %	18%	24%	23%
Interest expense	526.0m	559.0m	430.0m
Interest income	54.0m	31.0m	15.0m
Pre tax profit	3.5b	4.3b	4.4b
Income tax expense	775.0m	1.2b	962.0m
Net Income	2.7b	3.1b	3.4b

EUR	FY, 2017	FY, 2018	FY, 2019
Cash	3.1b	4.3b	2.2b
Accounts Receivable	3.1b	3.5b	4.2b
Prepaid Expenses	334.0m	377.0m	313.0m
Inventories	3.1b	3.3b	3.6b
Current Assets	10.7b	12.2b	11.2b
PP&E	3.9b	4.3b	4.8b
Goodwill	19.0m	26.0m	77.0m
Total Assets	28.4b	30.9b	33.5b
Accounts Payable	880.0m	855.0m	830.0m
Total Debt	439.0m	420.0m	256.0m
Total Liabilities	17.7b	18.6b	18.8b
Common Stock	178.0m	178.0m	178.0m
Total Equity	10.7b	12.3b	14.7b
Debt to Equity Ratio	0 x	0 x	0 x
Debt to Assets Ratio	0 x	0 x	0 x
Financial Leverage	2.7 x	2.5 x	2.3 x

EUR	FY, 2016	FY, 2017	FY, 2018	FY, 2019
Net Income	1.8b	(229.0m)	2.1b	2.7b
Depreciation and Amortization	620.0m	963.0m	1.1b	1.2b
Accounts Receivable	(315.0m)		(478.0m)	(590.0m)
Inventories	(249.0m)	305.0m	(229.0m)	(274.0m)
Accounts Payable	151.0m	(60.0m)	8.0m	9.0m
Cash From Operating Activities	2.9b	2.6b	3.0b	3.3b
Purchases of PP&E	(645.0m)	(872.0m)	(950.0m)	(1.1b)
Cash From Investing Activities	(133.0m)	(5.1b)	(1.4b)	(1.4b)
Long-term Borrowings	(722.0m)	(948.0m)	2.0m	(185.0m)
Cash From Financing Activities	(1.0b)	(1.2b)	(208.0m)	(1.0b)
Net Change in Cash	1.7b	(3.7b)	1.4b	894.0m
Income Taxes Paid	987.0m	1.1b	1.2b	1.1b

	FY, 2016	FY, 2017	FY, 2018	FY, 2019
Active Clinical Studies		500	400	400
Manufacturing Facilities (Animal Health)		19	16	16
Manufacturing Facilities (Human Pharmaceuticals)	19	16	20
New Products		200	300	200
Projects in Pipeline			90